RENO, Nev., July 12, 2005 (PRIMEZONE) -- Martin Nutraceuticals Inc. (Pink Sheets:MTNU) Director of Research and Development, Dr. A.W. Martin, announced today that further studies indicate additional benefits from the use of Martin Nutraceuticals proprietary and patented products.
Martin Nutraceuticals patented oral enzyme formulas are showing great promise in cancer prevention. Recent studies suggest that curcumin an active ingredient in Martin Nutraceutical enzyme formulas, as in Arthrizyme(tm), are showing great promise in recent studies according to the journal "Cancer."
These studies have shown beneficial effects of curcumin on skin cancer, breast cancer and even on Alzheimer's. In the study quoted in the journal "Cancer," researchers treated melanoma cells lined with curcumin at different doses and for different durations. Researchers have found that the nuclear factor called Kappa-B is turned "on" in cancer cells. The study found that the nuclear factor called Kappa-B is turned "off" in cells that have been lined with curcumin.
Dr. A. W. Martin DC, Ph.D., RNCP, D.N.M., Director of Research and Development for Martin Nutraceuticals attributes curcumin's success due to its anti-inflammatory properties. "Inflammation is now a major culprit in heart disease and several cancers. Inflammation can come from chronic injuries and the body's response to stress and toxicity. The addition of tumeric (a source of curcumin) to our systemic oral enzyme formulas has shown great anti-inflammatory properties. Systemic oral enzymes will be the treatment of choice for inflammation because of its effectiveness and safety record, whereas other prescription nonsteroidal medications cause far too many side effects," states Dr. Martin.
Arthrizyme(tm) will be available shortly for major distribution.
Forward Looking Statements
This release includes forward-looking statements and projections, made in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The company has made every reasonable effort to ensure that the information and assumptions on which these statements and projections are based are current, reasonable, and complete. However, a variety of factors could cause actual results to differ materially from the projections, anticipated results or other expectations expressed in this release, including, without limitation, the ability to implement and achieve our objectives in the long-range plan; actions by the credit rating agencies; the successful close of our financing transactions; our ability to divest of certain assets; inability to realize anticipated synergies and cost savings associated with restructurings and divestitures on a timely basis; the uncertainties associated with governmental regulation; the uncertainties associated with the outcome of governmental investigations; the outcome of pending litigation including shareholder derivative and class actions; difficulty in integration of the operations of previously acquired companies, and competition. While the company makes these statements and projections in good faith, neither the company nor its management can guarantee that anticipated future results will be achieved. The company assumes no obligation to publicly update or revise any forward-looking statements made herein or any other forward-looking statements made by the company, whether as a result of new information, future events, or otherwise.